21/07/2019
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has had a positive meeting with the FDA and remains on track to submit an NDA for arimoclomol for NPC in H1 2020. [...]
